Aragen Life Sciences Ltd. IPO Details
Aragen Life Sciences was incorporated on December 7, 2000. The company is a fully integrated CRDMO offering drug discovery, pre-clinical research, development and manufacturing solutions for small molecules and biologics, with over 25 years of experience. It serves global life sciences companies across key markets, including the US, Europe, Japan, India and APAC, and worked with 591 customers, including 16 of the top 20 Big Pharma companies, in FY26
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 27.3 M | - | - | ₹8,000.0 M | DRHP DOC |
Aragen Life Sciences issue details
Aragen Life Sciences has 27.3 M shares on offer
Aragen Life Sciences IPO issue size is ₹ 8,000.0 M
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Aragen Life Sciences IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Aragen Life Sciences NUMBER OF SHARES ON OFFER
Aragen Life Sciences FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY26 | 2,178.4 | 257.6 | 375.9 | 88.0 | 27.3% |
| FY25 | 1,845.1 | 180.4 | 335.7 | -33.7 | 25.6% |
| FY24 | 1,657.6 | 160.1 | 388.6 | 3.3 | 26.8% |
Aragen Life Sciences INFORMATION ON IPO ISSUE
About Aragen Life Sciences
Aragen Life Sciences was incorporated on December 7, 2000. The company is a fully integrated CRDMO offering drug discovery, pre-clinical research, development and manufacturing solutions for small molecules and biologics, with over 25 years of experience. It serves global life sciences companies across key markets, including the US, Europe, Japan, India and APAC, and worked with 591 customers, including 16 of the top 20 Big Pharma companies, in FY26
Object of the Issue
- Repayment and/or pre-payment, in part or full, of certain borrowings availed by the company and their material subsidiaries
- Capital expenditure to be incurred by the company for purchase of new equipment and machinery for the facilities in Hyderabad
- Capital expenditure to be incurred by one of their material subsidiaries, namely, Aragen Biologics Private Limited for the facility in Bengaluru towards purchase of new equipment and machinery for the following expansion of biologics drug substance capacity
- Capital expenditure to be incurred by one of their material subsidiaries, namely, Aragen Biologics Private Limited for the facility in Bengaluru towards purchase of new equipment and machinery for the following establishment of biologics drug product fill and finish capability
- General corporate purposes
Aragen Life Sciences - PROMOTERS
| Name |
|---|
| Davinder Singh Brar |
| Aparna Reddy Gunapati |
| Keshav Gunupati Venkat Reddy |
| Madhubani Investments Private Limited |
Aragen Life Sciences - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Davinder Singh Brar | Chairman & Non-Executive Non-Independent Director |
| Keshav Gunupati Venkat Reddy | Non-Executive Non-Independent Director |
| Manmahesh Kantipudi | Managing Director & CEO |
| Robert Richard Ruffolo | Non-Executive Independent Director |
| Ajay Srivastava | Non-Executive Independent Director |
| Anita Ramachandran | Non-Executive Independent Director |
| Amit Varma | Non-Executive Non-Independent Director |
| Shashank Surendra Sinha | Non-Executive Independent Director |
| Aaron Leigh Schacht | Non-Executive Independent Director |
Aragen Life Sciences Book Running Lead Manager
Axis Capital Limited
aragen.ipo@axiscap.in
Citigroup Global Markets India Private Limited
aragen.ipo@citi.com
Goldman Sachs (India) Securities Private Limited
aragenipo@gs.com
JM Financial Limited
aragenlife.ipo@jmfl.com
Aragen Life Sciences Registrar to the Offer
KFin Technologies Limited
aragenlifesciences.ipo@kfintech.com
Aragen Life Sciences Strengths
Diversified global customer base
The company serves a diversified global customer base of 591 customers, including 16 of the top 20 Big Pharma companies, with 95% of FY26 revenue coming from repeat business and long-standing customer relationships. Its diversified customer and geographic base, supported by strong client engagement and integrated services, helps reduce concentration risks and drive stable, recurring revenue
Integrated platform
The company operates the second-largest CRO solutions platform in India by scientific personnel and offers discovery solutions for small molecules and biologics, including chemistry, biology, safety assessment and specialized drug development services. Its expertise across multiple therapeutic areas and advanced modalities supports customers through various stages of drug discovery, with relatively high margins and shorter project cycles
CDMO capabilities & growth
The company has established CDMO capabilities for small molecules and biologics, with CDMO revenue growing at a 19.15% CAGR from FY24 to FY26. Its integrated platform covers custom synthesis, API development, formulations and GMP manufacturing, along with gene-to-GMP biologics services from cell line development to clinical and commercial manufacturing
Aragen Life Sciences Risks
Regulatory & quality risk
The company operates four globally approved manufacturing facilities that undergo periodic regulatory and customer inspections, with strict quality and technical requirements. Recent USFDA inspections identified Form 483 observations relating to quality control, process validation, cleaning, investigations and GMP compliance, and the Company has submitted responses within prescribed timelines
Competition & talent retnetion risk
The company relies heavily on skilled scientific personnel, with 4,362 employees including 3,412 scientific personnel and 479 PhDs as of March 31, 2026. Intense competition for specialised talent may increase hiring, training and employee costs, while difficulty in attracting or retaining skilled personnel could limit business expansion and revenue growth
Data security risk
The company handles sensitive customer information, including trade secrets, technical specifications and proprietary data, making confidentiality and data security critical to its operations. Any breach, unauthorised disclosure or intellectual property dispute could lead to customer loss, legal liabilities, reputational damage and adverse financial impact
IPO FAQs
The promoters of the company are Davinder Singh Brar, Aparna Reddy Gunapati, Keshav Gunupati Venkat Reddy and Madhubani Investments Private Limited.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.